title: Platelet function after single [153Sm]EDTMP therapy in prostate cancer.
abstract: OBJECTIVE
  Aim of the study was to assess whether [153Sm] EDTMP therapy at a low-dose is associated with platelet activation.
  
  
  METHODS
  In 29 patients suffering from metastatic prostate cancer platelet count and various platelet function parameters have been monitored for 2 months after a single (the first) application of 1.1 GBq mCi [153Sm]EDTMP.
  
  
  RESULTS
  After 3 days insignificant signs of platelet activation (increase in malondialdehyde, adenosine diphosphate-induced platelet aggregation, decreased platelet sensitivity) occur, normalizing rapidly. At the nadir of platelet count (3-4 weeks) platelet aggregation response in non-count adjusted samples is somewhat lower, while activity per cell (count adjusted samples) is unchanged. Platelet proteins do not change at all. Insignificant activation of platelet function at day 3 is interpreted as an indicator of mild oxidation injury, late aggregation response changes in non-adjusted samples seem only to reflect temporarily decreased number of circulating platelets. Samarium-153-EDTMP therapy at doses (1.1 GBq) used in the Vienna-protocol is not associated with a significantly altered functional behavior of platelets.
  
  
  CONCLUSIONS
  We conclude that a single dose of 1.1 GBq 153Sm-EDTMP does not significantly affect in vivo and ex vivo platelet function.
authors.affiliation: Department of Nuclear Medicine, Hospital Wr. Neustadt, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Weiss
authors.forename: B
authors.initials: B
authors.lastname: Palumbo
authors.forename: I
authors.initials: I
authors.lastname: Palumbo
authors.forename: R
authors.initials: R
authors.lastname: Palumbo
authors.forename: S
authors.initials: S
authors.lastname: Granegger
authors.forename: J
authors.initials: J
authors.lastname: Hiltunen
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000368:Aged; D001792:Blood Platelets / Q000528:radiation effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D015539:Platelet Activation / Q000528:radiation effects*; D010976:Platelet Count; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000097:blood / Q000209:etiology; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals; C061972:samarium Sm-153 lexidronam